ClinicalTrials.gg

Program

BET Inhibitor JAB-8263

Its studies are mostly in Arthritis, Rheumatoid · Ovarian Neoplasms, led by Jacobio Pharmaceuticals.

Furthest: phase 2, since Dec 23, 20203 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jacobio Pharmaceuticals32 open or runningphase 2since Dec 23, 2020Oct 9, 2020Jun 30, 2027phase 2 · NCT07684157

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 9, 2020First study: phase 1 study in Solid Tumors, AdultFirst studyNCT04587479 · 41 enrolled · United States
  2. Dec 23, 2020Phase 2 study in Ovarian NeoplasmsNCT04686682 · 152 planned · China
  3. Jun 29, 2026Phase 2 study in Arthritis, RheumatoidNCT07684157 · 32 planned · China

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT07684157
  2. Jan 2028Primary completion: phase 2 study in Ovarian NeoplasmsNCT04686682

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07684157Arthritis, Rheumatoid · China2RecruitingJun 30, 202732
NCT04686682Ovarian Neoplasms · China2RecruitingJan 2028152
NCT04587479Solid Tumors, Adult · United States1CompletedOct 31, 202441

How it is read

Names in the registry

  • “JAB-8263”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.